Yeztugo
Gilead Wins Groundbreaking FDA Approval for Twice-Yearly HIV Prevention Shot
Gilead; FDA approval; lenacapavir; Yeztugo; HIV prevention; twice-yearly injection; PrEP; long-acting injectable; WHO guidelines
FDA Approves Gilead’s Twice-Yearly HIV Prevention Shot
FDA approval; Gilead Sciences; Lenacapavir; Yeztugo; HIV prevention; twice-yearly injection; PrEP; public health